Non-Insured Health Benefits (NIHB) Newsletter for Pharmacy Providers - Fall 2005
News and Information for our NIHB providers
NIHB toll-free inquiry centre: 1-888-511-4666
For Our Pharmacy Providers - Fall 2005
News and Views
Welcome to the fall 2005 edition of the Non-Insured Health Benefits
(NIHB) quarterly newsletter. First Canadian Health (FCH) is now
in its seventh year of operations as the claims processor for the
NIHB Program of the First Nations and Inuit Health Branch (FNIHB)
of Health Canada.
Again, FCH would like to thank you for your support as you continue
to provide quality health services to First Nations and Inuit clients
of the NIHB Program.
As always, your comments and questions are welcome. Please contact
the FCH NIHB Toll-Free Inquiry Centre at 1-888-511-4666,
or send your correspondence to:
FCH Provider Relations
3080 Yonge Street, Suite 3002
Toronto, ON M4N 3N1
Fall 2005 NIHB Drug Benefit List (DBL) Updates
These updates include the addition and replacement of Drug Identification
Numbers (DIN), limited use benefits, drugs removed from the Canadian
market, and drugs discontinued by the manufacturer effective October
1, 2005.
These updates are
reflected in the most recent electronic version of the NIHB DBL. Please refer to the website at the following address:
www.hc-sc.gc.ca/fnih-spni/pubs/drug-med/drug-med_list/index_e.html
Should you have any questions, please contact the FCH NIHB Toll-Free
Inquiry Centre at 1-888-511-4666.
![To Top](/web/20061213093324im_/http://hc-sc.gc.ca/images/fnih-spni/arrow_up.gif)
New Drug Utilization review (DUR) Warning Message NE - Potential
Overuse/Abuse Indicated
By the end of 2005, the DUR information returned to the provider
will include the Canadian Pharmacists Association (CPhA) response
code NE, which indicates potential overuse/abuse of specified drug
entities. The warning code will not prevent the payment of claims,
but will provide pharmacists with additional information concerning
potential problems related to the current drug claim. The new warning
code and message will be sent to providers for claims that meet
the criteria below:
- Use of methadone for treatment of opioid dependency (pseudo-din
00908835) and, at the same time, use of one or more narcotic
drug entities.
- Use of three (3) or more different narcotic drug entities.
- Use of three (3) or more different benzodiazepine drug entities.
- Use of three (3) or more narcotic drug entities and three (3)
or more benzodiazepine drug entities.
Should you have any questions, please contact the FCH NIHB Toll-Free
Inquiry Centre at 1-888-511-4666.
![To Top](/web/20061213093324im_/http://hc-sc.gc.ca/images/fnih-spni/arrow_up.gif)
Documentation for Overriding Rejected Claims
Currently, claim submissions which generate the following messages
during Drug Utilization Review (DUR) - termed Drug Use Analysis
(DUA) in Quebec - are rejected:
- Duplicate Drug (MW)
- Duplicate Drug Multi Pharmacy (MY)
- Drug/Drug Interaction Potential (ME)
Following a review and, based on his/her professional judgment,
the provider can override the rejection by re-submitting the rejected
claim with a valid CPhA intervention code.
In the Fall 2001 Newsletter, the NIHB Program specified that,
for each of these interventions, providers must complete and retain
appropriate documentation. This may be documented either directly
on the prescription or on any hard copy or electronic version of
the patient profile. The Newsletter article also indicated that
the information was to be available for review, if required, during
the claims verification/auditing process.
Lack of documentation of DUR overrides continues to be a significant
audit finding. Therefore, providers are reminded that interventions
which lack supporting DUR documentation, are subject to reclaim.
![To Top](/web/20061213093324im_/http://hc-sc.gc.ca/images/fnih-spni/arrow_up.gif)
Appeal Process
When a client is denied a benefit, there are three levels of appeal
available under the NIHB Program. Providers are reminded that appeals
can only be initiated by the client, or with written confirmation
that the client is aware that the appeal is being submitted on
his/her behalf. Appeals submitted by providers without client confirmation
will not be subject to review.
Providers can download a current version of the NIHB
Pharmacy/Medical Supplies and Equipment Provider Information
Kit (PPIK)
that contains revised Sections 2, 3 and 4, as well as the revised
table of contents at the NIHB website:
www.hc-sc.gc.ca/fnih-spni/pubs/drug-med/2005_kit-trousse_info/index_e.html
Providers without internet access can contact the FCH NIHB Toll-Free
Inquiry Centre at 1-888-511-4666.
Published quarterly by First
Canadian Health Management Corporation Inc. at 3080
Yonge Street, Suite 3002, Toronto ON M4N 3N1
|